| GTO ID | GTC1877 |
| Trial ID |
NCT03483103
|
| Disease |
Non-Hodgkin's Lymphoma
|
B-Cell Lymphoma
|
Diffuse Large B-Cell Lymphoma
|
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | Breyanzi|Lisocabtagene maraleucel|liso-cel|JCAR017 |
| Location approved | US, Japan, EU, Switzerland, UK, Canada |
| Generation | 2nd |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006) |
| Year | 2018 |
| Country | United States |
| Company sponsor | Juno Therapeutics, a Subsidiary of Celgene |
| Other ID(s) | 17006 |